SGLT-2 and DPP-4 inhibitors were associated with a lower risk of dementia, whereas GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors were associated with reduced dementia-related mortality. This evidence concerns the gene DPP4 and dementia.